Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	22.13	23.01	27.88	30.34	50.94
Short-Term Investments	-	-	0.02	13.32	9.79
Cash & Short-Term Investments	22.13	23.01	27.89	43.66	60.73
Cash Growth	-3.79%	-17.52%	-36.12%	-28.11%	326.48%
Other Receivables	0.13	0.72	0.8	0.55	0.53
Receivables	0.13	0.72	0.8	0.55	0.53
Prepaid Expenses	0.45	0.28	0.6	0.72	0.34
Other Current Assets	-	-	-	0.35	0.77
Total Current Assets	22.71	24.01	29.29	45.28	62.37
Property, Plant & Equipment	0	0.01	0.57	0.57	0.09
Goodwill	8.14	8.14	8.14	12.96	-
Other Intangible Assets	41.14	41.15	41.13	69.81	-
Total Assets	71.99	73.3	79.12	128.62	62.46
Accounts Payable	0.6	1.01	1.24	1.68	0.12
Accrued Expenses	1.33	0.68	2.09	1.48	1.38
Current Portion of Leases	-	-	0.08	0.1	0.09
Total Current Liabilities	1.93	1.68	3.41	3.26	1.58
Long-Term Leases	-	-	0.41	0.19	-
Long-Term Deferred Tax Liabilities	2.31	5.51	7.35	16.89	-
Other Long-Term Liabilities	1.14	4.36	-	0.01	5.22
Total Liabilities	5.38	11.56	11.17	20.35	6.8
Common Stock	0	0	258.29	257.99	197.19
Additional Paid-In Capital	293.33	278.9	13.97	12.15	10.82
Retained Earnings	-220.69	-211.12	-198.27	-155.84	-146.02
Comprehensive Income & Other	-6.04	-6.04	-6.04	-6.04	-6.33
Shareholders' Equity	66.61	61.74	67.96	108.27	55.66
Total Liabilities & Equity	71.99	73.3	79.12	128.62	62.46
Total Debt	-	-	0.49	0.3	0.09
Net Cash (Debt)	22.13	23.01	27.41	43.37	60.65
Net Cash Growth	-3.79%	-16.05%	-36.80%	-28.49%	330.32%
Net Cash Per Share	1.83	2.41	3.69	7.06	24.54
Filing Date Shares Outstanding	13.83	9.4	7.44	7.38	4.34
Total Common Shares Outstanding	13.72	9.4	7.44	7.38	4.34
Working Capital	20.78	22.33	25.88	42.02	60.79
Book Value Per Share	4.86	6.57	9.14	14.67	12.82
Tangible Book Value	17.33	12.46	18.69	25.5	55.66
Tangible Book Value Per Share	1.26	1.33	2.51	3.45	12.82
Machinery	0.01	0.61	0.67	0.7	-

Updated Jun 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q